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 2 
Abstract 47 
 48 
The soluble receptor for advanced glycation endproducts (sRAGE) may be protective 49 
against inflammation associated with obesity and type 2 diabetes (T2DM).  The aim of 50 
this study was to determine the distribution of sRAGE isoforms, and whether sRAGE 51 
isoforms are associated with risk of T2DM development in subjects spanning the 52 
glucose tolerance continuum. In this retrospective analysis, circulating total sRAGE and 53 
endogenous secretory RAGE (esRAGE) were quantified via ELISA and cleaved RAGE 54 
(cRAGE) was calculated in 274 individuals stratified by glucose tolerance status (GTS) 55 
and obesity. Group differences were probed by ANOVA and multivariate ordinal logistic 56 
regression was used to test the association between sRAGE isoform concentrations 57 
and the proportional odds of developing diabetes, versus normal glucose tolerance 58 
(NGT) or impaired glucose tolerance (IGT). When stratified by GTS, total sRAGE, 59 
cRAGE, and esRAGE were all lower with IGT and T2DM, while the ratio of cRAGE to 60 
esRAGE (cRAGE:esRAGE) was only lower (p<0.01) with T2DM compared to NGT. 61 
When stratified by GTS and obesity, cRAGE:esRAGE was higher with obesity and 62 
lower with IGT (p<0.0001) compared to lean, NGT. In ordinal logistic regression models, 63 
greater total sRAGE (odds ratio: 0.91; p<0.01) and cRAGE (odds ratio: 0.84; p<0.01) 64 
were associated with lower proportional odds of developing T2DM. Reduced values of 65 
sRAGE isoforms observed with both obesity and IGT are independently associated with 66 
greater proportional odds of developing T2DM. The mechanisms by which each 67 
respective isoform contributes to obesity and insulin resistance may reveal novel 68 
treatment strategies for diabetes. 69 
 70 
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Introduction 91 
The study of advanced glycation end products (AGE) and their receptor (RAGE) 92 
has maintained scientific interest over the past several decades given evidence 93 
implicating them both as important contributors to the development, and progression of 94 
complications associated with diabetes (8, 33, 45). Initiation of inflammation and 95 
generation of reactive oxygen species as a consequence of RAGE activation is well 96 
documented (39). Despite numerous attempts, targeting RAGE directly as a therapeutic 97 
strategy has largely been unsuccessful (11). However, RAGE signaling can be 98 
interrupted, in vivo, by directed proteolytic cleavage of the RAGE ectodomain (cleaved 99 
RAGE: cRAGE) (16, 32), thus creating a soluble isoform of RAGE (sRAGE) that is 100 
released from the cell and appears into the circulation (32). In addition, alternative 101 
splicing of the RAGE gene at exon 9 produces a truncated c-terminus protein product 102 
(endogenous secretory RAGE: esRAGE) that is expelled from the cell via exocytosis 103 
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(56). This heterogeneous pool of solubilized receptors, collectively termed total sRAGE, 104 
serves to down-regulate the inflammatory response by absorbing excess RAGE ligands, 105 
thus attenuating cell membrane RAGE signaling. The production of soluble receptors, 106 
as a general concept, is regarded as a common feature of cytokine biology with 107 
significant implications for inflammatory disease progression and therapy. Thus, 108 
maintaining high levels of circulating sRAGE isoforms is apparently advantageous for 109 
the organism (14, 17, 48). This is exemplified, in-part, by data demonstrating sRAGE 110 
isoforms are decreased in inflammatory conditions such as type 2 diabetes mellitus 111 
(T2DM), coronary artery disease (CAD), and neurodegenerative diseases (14, 48, 54), 112 
while treatment with recombinant sRAGE (R-sRAGE), suppresses atherosclerosis and 113 
vascular dysfunction in animal models of diabetic CAD (34) .  114 
Given this evidence, efforts have been made to establish the efficacy of sRAGE 115 
isoforms as biomarkers for diabetes and associated complications. However, existing 116 
clinical data are equivocal, possibly due to low sample size, lack of metabolic control 117 
measures and incomplete phenotyping. For example, several studies have 118 
demonstrated no difference or even elevated total sRAGE levels in T2DM compared to 119 
BMI-matched controls with no relationship to basic measures of insulin sensitivity such 120 
as HOMA-IR (4, 18). Alternatively, attenuated total sRAGE has been independently 121 
reported with obesity, pre-diabetes, and T2DM (5, 13, 40), and low total sRAGE was 122 
associated with greater risk of developing T2DM and cardiovascular mortality of non-123 
diabetic individuals (40). 124 
What these prior studies lack are normative values of sRAGE isoforms derived 125 
from a population of young, lean, and physically active adults, which is generally 126 
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regarded as the ideal state of human health. Further, no studies have yet to examine 127 
the independent effects of body composition or obesity on all sRAGE isoforms, nor have 128 
sRAGE isoforms been comprehensively examined across the glucose tolerance 129 
continuum, which underlies the natural history of T2DM. In addition, the relationships 130 
between sRAGE isoforms and insulin sensitivity remains ambiguous, potentially due to 131 
reliance on fasting indices of insulin sensitivity, such as HOMA-IR. Finally, cRAGE and 132 
esRAGE data are seldom reported together and the ratio of cRAGE to esRAGE 133 
(cRAGE:esRAGE) has yet to be explored as a potential index for insulin resistance or 134 
risk of developing T2DM. The latter may be particularly insightful given the mechanistic 135 
differences by which cRAGE and esRAGE are generated in vivo. Therefore, our aim 136 
was to characterize total sRAGE, cRAGE, esRAGE and cRAGE:esRAGE in a young, 137 
lean healthy reference group, as well as individuals stratified according to glucose 138 
tolerance status (GTS), obesity or both. We hypothesized that sRAGE isoforms would 139 
be reduced with impaired glucose tolerance (IGT) and T2DM and further reduced in the 140 
presence of obesity in comparison to a lean healthy reference group. Further, we 141 
assessed whether the circulating concentrations of sRAGE isoforms were associated 142 
with greater odds of developing T2DM. 143 
Material and Methods 144 
Study Design and Subjects  145 
This data set examines 274 individuals from whom we have quantified circulating 146 
sRAGE isoform concentrations. Demographic and clinical data from some subjects 147 
participating in this work have been published (25, 31, 41, 42, 53). However, this is the 148 
first reporting of the sRAGE data in these subjects. Our intent was to examine sRAGE 149 
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isoforms and insulin sensitivity in a population of overweight and obese subjects that 150 
spanned the glucose tolerance continuum (NGT, IGT, T2DM), and directly contrast 151 
these observations with a group of young, lean healthy controls (LHC), who performed 152 
at least 120 minutes of moderate intensity physical activity per week. We interpret the 153 
LHC group to represent an optimal state of health and thus provide a benchmark of 154 
“normal” sRAGE isoform concentrations. Potential participants underwent medical 155 
screening to determine their eligibility for the study, which included a medical history 156 
assessment, electrocardiogram, and blood chemistry screening. Evidence of prior or 157 
current chronic pulmonary, hepatic, renal, gastrointestinal, or hematological disease, 158 
weight loss (>2 kg within 6 months), smoking, and contraindication to an exercise test 159 
were used as exclusion criteria. Blood glucose following a 2-hour oral glucose tolerance 160 
test (OGTT) was used to stratify subjects by GTS according to the American Diabetes 161 
Association (ADA) (2). However, T2DM stratification relied on ADA criteria, prior clinical 162 
diagnosis, or use of prescription anti-diabetic medication. Body mass index (BMI) was 163 
used to stratify subjects by obesity status (lean < 25 kg/m2, overweight 25 – 29 kg/m2, 164 
or obese > 29 kg/m2). Subjects were recruited by newspaper/radio advertisement from 165 
the local municipal areas in Chicago, Illinois, Cleveland, Ohio, USA and Copenhagen, 166 
Denmark. All subjects provided oral and written informed consent prior to participation, 167 
and the methods were approved by local ethics committees at all locations (Institutional 168 
Review Boards of the University of Illinois at Chicago and Cleveland Clinic and the 169 
Scientific Ethics Committee of the Capital Region of Denmark). 170 
Pre-Test Control Period 171 
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Tests took place in the Clinical Research Units of the University of Illinois at 172 
Chicago and Cleveland Clinic, and at the Clinical Research Laboratory of the Centre of 173 
Inflammation and Metabolism, Rigshospitalet, Denmark. Subjects being treated with 174 
anti-diabetic drugs withheld their medications for at least 24 hours prior to metabolic 175 
testing. Diet and physical activity records were taken in an outpatient setting and all 176 
subjects were instructed to abstain from consuming alcohol 48 hours prior to their visit 177 
and not to consume caffeine within 24 hours of their visit. Subjects also abstained from 178 
structured exercise for at least 24 hours prior to metabolic testing. 179 
Clinical Procedures 180 
 Height and weight were measured using standard techniques. Whole body 181 
adiposity was estimated using dual-energy x-ray absorptiometry (Lunar iDXA, GE 182 
Healthcare, Madison, WI, USA). Subjects performed an incremental treadmill exercise 183 
test to determine their maximal oxygen consumption (VO2max) as described previously 184 
(43). The VO2max test was conducted at least 48-hours prior to subsequent metabolic 185 
assessments. On a separate day, following an 8-10 hour overnight fast, subjects came 186 
to the laboratory and an antecubital venous cannula was placed for baseline blood 187 
collection. Subjects ingested 75 g of anhydrous glucose dissolved in 300 mL water 188 
(standard OGTT). Following glucose ingestion, regular venous blood samples were 189 
collected for 2 hours. Blood was centrifuged at 2000 g for 15 min at room temperature 190 
and respective serum/plasma was stored at -80oC until analysis. In addition, insulin 191 
sensitivity was measured in 80 subjects via hyperinsulinemic (40mU/m2/min)-192 
euglycemic (5 mmol/L) clamp. The methods of the hyperinsulinemic-euglycemic clamp 193 
were described previously (31, 53). 194 
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Blood Analyses 195 
Glucose concentrations were measured using a bed-side analyzer (YSI Stat, 196 
Yellow Springs, USA; ABL, Radiometer, Denmark); insulin concentrations were 197 
determined by electrochemiluminescence immunoassay (E-modular; Roche, 198 
Switzerland) and radioimmunoassay (Millipore, Billerica, MA, USA); glycated 199 
hemoglobin (HbA1c) levels were determined by high performance liquid chromatography 200 
(HPLC) (Tosoh G7 analyzer; San Francisco, CA, USA). High sensitive C-reactive 201 
protein (hs-CRP) was determined via ELISA (Alpha Diagnostics International, San 202 
Antonio, TX, USA). Total sRAGE concentrations were measured in plasma samples by 203 
commercial ELISA (R&D Systems Inc., Minneapolis, MN, USA) as per the 204 
manufacturer’s protocol. This measure of total human sRAGE levels includes both the 205 
cleaved (cRAGE) and spliced variants (esRAGE). A monoclonal antibody raised against 206 
the N-terminal of the extracellular domain of RAGE, comprising amino acids 24-344, 207 
was used to detect the sRAGE in the sample (R&D Systems Inc.). Plasma esRAGE 208 
concentrations were measured separately by commercial ELISA (As One International, 209 
Mountain View, CA, USA) as per the manufacturer’s protocol. A monoclonal antibody 210 
raised against human esRAGE, recognizing amino acids 332-347 was used to detect 211 
esRAGE in the sample (B-Bridge International). Plasma cRAGE concentrations were 212 
then determined by subtracting esRAGE from total sRAGE as previously described (47, 213 
55). The sRAGE ratio (cRAGE:esRAGE) was derived by the quotient of cRAGE to 214 
esRAGE and expressed in arbitrary units. All samples were analyzed in duplicate.  215 
Statistics 216 
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All data was tested for normality using Shapiro-Wilk’s test. Parametric or non-217 
parametric statistical tests were applied accordingly. Subject characteristics for each 218 
group were compared using a one-way ANOVA. One-way ANOVA was also used to 219 
compare mean sRAGE isoform data between groups. The effects of obesity (lean, 220 
overweight, obese) and glucose tolerance status (NGT, IGT, T2DM) on sRAGE 221 
isoforms were determined via two-way ANOVA. Bonferroni/Dunn post hoc tests were 222 
used for multiple comparisons when appropriate. Multivariate ordinal regression 223 
modeling was used to determine if sRAGE isoforms could predict risk of diabetes 224 
progression using stratification by glucose tolerance status and adjustment for age, race 225 
and obesity (proportional odds model) (52). Caucasian was used as the reference for 226 
race, and lean was used as the reference for obesity status. Total sRAGE, esRAGE, 227 
cRAGE and cRAGE:esRAGE were used to construct models. The values for total 228 
sRAGE, cRAGE and esRAGE were multiplied by 100 before entering them into the 229 
models. To avoid co-linearity, we did not generate a stepwise model that included all 230 
sRAGE measures in the model. Homogeneity of the odds ratios was confirmed for all 231 
variables prior to performing ordinal regression. Bivariate correlation analyses were 232 
performed using Pearson or Spearman correlation coefficients. SPSS v24 (IBM, 233 
Armonk, NY, USA) and SAS (Cary, NC, USA) were used to perform statistical analyses. 234 
p < 0.05 was considered significant and data are presented as mean ± SD. 235 
Results 236 
Subject Characteristics 237 
Table 1 shows subject characteristics stratified by GTS. Markers of glycemic 238 
control (HbA1c, 2-h OGTT glucose and fasting glucose) were progressively increased 239 
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across the glucose tolerance continuum. The IGT and T2DM groups were of similar 240 
age, BMI, and fitness level (VO2Max) (Table 1; p>0.05). By design, compared to the IGT 241 
and T2DM groups, the NGT group was younger, leaner (BMI), more fit (VO2Max) and had 242 
superior glycemic control apart from 2-h OGTT glucose iAUC, which was not different 243 
from T2DM (Table 1). Further details of subject characteristics including gender and 244 
race frequencies in each group are provided in Table 2.  245 
sRAGE Isoforms are Attenuated with Impaired Glucose Tolerance 246 
  When stratified by GTS, NGT individuals had 33% (SD 37%) greater total 247 
sRAGE compared to IGT individuals (p<0.05) and 31% (SD 29%) greater total sRAGE 248 
compared to T2DM individuals (p<0.05; Figure 1A). cRAGE and esRAGE, which 249 
comprise total sRAGE, were lower to a similar extent in IGT and T2DM compared to 250 
NGT individuals (p<0.05; Figure 1B and C). However, cRAGE:esRAGE was only lower 251 
in T2DM compared to NGT subjects pointing to a disproportionate lack of cRAGE in 252 
T2DM individuals (p<0.05; Figure 1D). This observation is significant considering that 253 
cRAGE made up 63% (SD 12.5%) of total sRAGE in subjects with T2DM.  254 
Increased circulating sRAGE Isoforms are associated with reduced 255 
proportional odds of developing diabetes  256 
We had hypothesized that reduced sRAGE isoforms may underlie the natural 257 
history of T2DM according to progression across the glucose tolerance continuum. 258 
Using ordinal logistic regression analysis (Table 3), total sRAGE (Model 1), cRAGE 259 
(Model 2), esRAGE (Model 3), and cRAGE:esRAGE (Model 4) were combined with 260 
other independent variables (age, race, obesity) to form each respective model. As 261 
expected, and shown previously, both age and race were associated with greater 262 
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proportional odds (Table 3) for the development of T2DM (19). For total sRAGE, 263 
cRAGE, and cRAGE:esRAGE, each were independently associated with the 264 
proportional odds for progression across the glucose tolerance continuum to T2DM, 265 
whereas esRAGE was not. A 100 pg/mL increase in total sRAGE was associated with a 266 
9% reduction in the proportional odds of developing T2DM, whereby the same increase 267 
in cRAGE was associated with a 16% reduction (Table 3). Additionally, every 1 unit 268 
increase in cRAGE:esRAGE predicted a 26% decreased risk of diabetes progression 269 
(Table 3). The model demonstrating the greatest reduction in proportional odds was 270 
Model 2 that included cRAGE isoforms (C-Statistic 0.805; Table 3). 271 
Relationships with sRAGE isoforms and Metabolic Variables 272 
Bivariate correlation analyses between sRAGE variables and metabolic variables 273 
are presented in Table 4. Total sRAGE, cRAGE, and esRAGE negatively correlated 274 
with BMI and percent body fat with esRAGE having the strongest relationships between 275 
both variables. In addition, all sRAGE variables were positively correlated with 276 
cardiorespiratory fitness (VO2Max). Positive correlations between cRAGE:esRAGE, 277 
VO2Max and BMI again demonstrate that the proportion of cRAGE and esRAGE 278 
isoforms, rather than just the independent quantity of each, is related to fitness level, 279 
and body weight status.  280 
Apart from 2-h OGTT iAUC, total sRAGE and cRAGE negatively correlated with 281 
clinical markers of glycemic control (2-h OGTT glucose, HbA1c, fasting glucose, fasting 282 
insulin, and HOMA-IR). On the other hand, esRAGE negatively correlated with 2-h 283 
OGTT iAUC, HbA1c, and fasting glucose whereas sRAGE ratio positively correlated with 284 
2-h OGTT iAUC, and negatively correlated with 2-h OGTT glucose, fasting glucose and 285 
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HOMA-IR. Finally, total sRAGE, esRAGE, and cRAGE all positively correlated with 286 
Matsuda index; however, the strongest associations with insulin sensitivity were found 287 
between clamp-derived glucose disposal rate (GDR) and total sRAGE (rho=0.472, 288 
p<0.001), cRAGE (rho=0.343, p=0.003), and esRAGE (rho=0.594, p <0.001). GDR also 289 
negatively correlated with cRAGE:esRAGE (rho=-0.276, p=0.018). 290 
sRAGE Isoforms are Reduced with Worsening Obesity Status 291 
Because the glucose tolerance groups were heterogeneous with regard to 292 
obesity, we further stratified by obesity status to isolate the sRAGE phenotype of lean 293 
NGT individuals. Because of low sample size in the overweight subgrouping, the IGT 294 
group was combined with T2DM (IGT-T2DM) and overweight was combined with obese 295 
(Overweight-Obese) (Figure 2). Using a 2-way (glucose tolerance x obesity) ANOVA, 296 
obesity status displayed a group effect for esRAGE (p=0.001) and cRAGE:esRAGE 297 
(p<0.0001). A group effect was also seen for GTS on total sRAGE (p<0.0001), cRAGE 298 
(p<0.0001), esRAGE (p=0.026), and cRAGE:esRAGE (p<0.0001), and an interaction 299 
effect was observed for total sRAGE (p=0.002), cRAGE (p=0.001), esRAGE (p=0.048), 300 
and cRAGE:esRAGE (p=0.032).  301 
Lean, NGT individuals displayed the highest concentration of total sRAGE 302 
(Figure 2A), cRAGE (Figure 2B), and esRAGE (Figure 2C), compared to all other 303 
subgroups. The largest deviation from lean, NGT individuals when examining cRAGE 304 
was found in Lean, IGT-T2DM (61%, SD 16%). However, the largest deviation of 305 
esRAGE from lean, NGT individuals was found in Overweight-Obese, IGT-T2DM 306 
individuals (36%, SD 36%). Comparison of cRAGE:esRAGE between groups revealed 307 
the largest ratio exists in the Overweight-Obese, NGT group (Figure 2D). This increase 308 
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in cRAGE:esRAGE ratio indicates a preferential decrease in esRAGE related to 309 
worsening obesity status. Full analyses of the individual group stratifications and 310 
alternative sub groupings were performed and statistically interrogated via ANOVA. 311 
However, these analyses did not offer any insight beyond the results presented here. 312 
We also analyzed the concentration of sRAGE isoforms across obesity status 313 
alone by stratifying individuals into lean, overweight or obese groups. Individuals who 314 
were overweight or obese had similar concentrations of sRAGE isoforms and 24-35% 315 
lower concentrations of sRAGE isoforms compared to lean individuals (p<0.05). Being 316 
that the NGT group was significantly younger than the IGT and T2DM groups (Table 2). 317 
Lastly, we examined the effect of age on sRAGE isoforms by stratifying individuals into 318 
young (18-35 y), middle-aged (36-64 y), and older (65 y) groups. Concentration of 319 
sRAGE isoforms were similar between middle-aged and older individuals but were 25-320 
45% lower compared to young individuals (p<0.05). Interestingly, older individuals had a 321 
lower cRAGE:esRAGE ratio compared to both young and middle-aged individuals 322 
(p<0.05). Given this analysis demonstrated a significant effect of age on sRAGE 323 
isoforms, we examined the effect of GTS on sRAGE measures while co-varying for age 324 
as a continuous variable. The results of this analysis eliminated all significant effects of 325 
GTS on esRAGE and cRAGE:esRAGE concentration (p>0.05). In addition, the 326 
difference between total sRAGE and cRAGE in NGT compared to IGT groups that exist 327 
in Figure 1 were also resolved. However, even after controlling for age, individuals with 328 
T2DM still possess significantly lower total sRAGE and cRAGE compared to NGT 329 
individuals. All sRAGE isoforms were also negatively correlated with age (Table 4).  330 
Discussion 331 
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To our knowledge, the current study is the first to report circulating 332 
concentrations of both major sRAGE isoforms (cRAGE and esRAGE) in the context of 333 
obesity and T2DM. Our primary finding was that lean, NGT individuals possessed the 334 
greatest concentration of sRAGE isoforms compared to states of obesity, IGT, T2DM or 335 
both. These findings are in accord with previous reports of lower sRAGE with obesity (5, 336 
13, 18) and impaired glucose tolerance (3, 12, 22, 46). Importantly, we also 337 
demonstrate for the first time that reduced circulating concentrations of sRAGE isoforms 338 
are associated with greater proportional odds for the development of T2DM.  339 
To this end, we developed ordinal logistic regression models using the sRAGE 340 
isoforms and cRAGE:esRAGE as independent variables to determine the proportional 341 
odds ratio of progression across the glucose tolerance continuum to T2DM. GTS is 342 
interpreted as having set thresholds along a range of possible outcomes according to 343 
American Diabetes Association criteria for the diagnosis of T2DM, thus meeting the 344 
assumption needed for ordinal regression (52). The application of this type of statistical 345 
model allows for hypothesizing movement along a known continuum (using proportional 346 
odds) without longitudinal follow-up. Importantly, our analyses revealed that a 100 347 
pg/mL increase in total sRAGE and cRAGE resulted in a marked risk reduction for 348 
progression across the glucose tolerance continuum. For calibration, 100 pg/mL 349 
represents 12% of the cRAGE concentration in lean NGT individuals. Given our 350 
regression model, the lower cRAGE observed in IGT subjects (276 pg/mL) equates to 351 
~44% increased proportional odds of progression towards T2DM. Our sample size was 352 
relatively small and our sampling was cross-sectional so these data must be interpreted 353 
with caution. However, Selvin et al. reported similar findings in a sample of 1,200 354 
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individuals without T2DM, whereby those in the lowest quartile of total sRAGE 355 
concentration had an increased risk of developing T2DM 18 years later (hazard ratio 356 
1.64; 95% CI: 1.10-2.44) (40). Further, the relationships between modulation of sRAGE 357 
and health outcomes have been reported, whereby increased sRAGE, following a 12-358 
wk aerobic exercise intervention, was associated with reduced C-reactive protein and 359 
improved aerobic fitness (9). Given the financial and time burden for longitudinal studies 360 
such as the latter, the application of ordinal regression models has merit for 361 
identification and characterization of novel targets such as sRAGE isoforms. Here, we 362 
expand on previous observations by demonstrating cRAGE as the isoform with the 363 
greatest ability to predict risk of progression across the glucose tolerance continuum 364 
whereas esRAGE did not. These data suggest dichotomous roles for cRAGE and 365 
esRAGE isoforms and their relevance to T2DM. 366 
In line with this notion, we provide novel evidence of a disproportionate loss of 367 
cRAGE and esRAGE in the case of T2DM and obesity respectively. Although both 368 
cRAGE and esRAGE were significantly lower in IGT and T2DM compared to NGT 369 
individuals, only the T2DM group possessed a significantly lower cRAGE:esRAGE ratio. 370 
Additionally, when examining the effects of obesity and GTS on sRAGE measures, 371 
there was a significant effect of GTS on cRAGE:esRAGE ratio whereby impaired 372 
glucose tolerance tended to result in a lower ratio, implying a preferential loss of cRAGE 373 
(Figure 2). The lean, IGT-T2DM group stratification also possessed the lowest 374 
concentration of cRAGE compared to all other perturbations. Additionally, cRAGE 375 
correlated with 2h OGTT glucose and HOMA-IR whereas esRAGE did not. Collectively, 376 
these data suggest that loss of cRAGE is strongly influenced by IGT and T2DM.  377 
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The observed cRAGE phenotype may be mediated by a preferential attenuation 378 
of cRAGE-producing mechanisms with IGT and T2DM, specifically the proteolytic 379 
cleavage of the RAGE ectodomain via the enzyme A Disintigrin and Metalloproteinase 380 
10 (ADAM10) or other matrix metalloproteinases (16, 32, 37). ADAM10 is the primary 381 
enzyme responsible for cRAGE production (37). Retinoic acid receptor beta (RAR) 382 
positively regulates ADAM10 transcription by binding to its promoter site (28, 49). 383 
Deacetylation of RAR, is necessary for this action and is mediated by the deacetylase 384 
activity of SIRT1 (10, 28). SIRT1 plays a role in beta cell insulin secretion and insulin 385 
sensitivity in other tissues such as fat and skeletal muscle(27). Importantly, SIRT1 386 
expression is reduced in T2DM and is also down regulated by RAGE signaling (21, 50). 387 
Activation of RAGE signaling occurs via binding of its ligands such as AGEs. These 388 
RAGE ligands are known to be elevated in the T2DM condition, and have been related 389 
to insulin resistance (45). Specifically, exposure to the RAGE ligands reduces SIRT1 390 
protein expression in the liver, skeletal muscle and adipose, resulting in the 391 
development of insulin resistance in these tissues (7).  392 
In the current study, cRAGE correlated to GDR (r=0.343, p=0.003) (Table 4) and 393 
its reduction was strongly associated with the proportional odds for progression through 394 
the glucose tolerance continuum (Table 3). GDR is the gold standard measure for 395 
insulin-mediated glucose disposal which is largely dictated by the insulin sensitivity of 396 
the skeletal muscle. Therefore, failure of the cRAGE producing mechanisms such as 397 
RAR, SIRT1, and ADAM10 in the skeletal muscle may allow for excessive RAGE 398 
signaling to promote the development of insulin resistance in skeletal muscle. This may 399 
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help explain why higher cRAGE is strongly related to insulin sensitivity and lower 400 
cRAGE is related to the progression toward T2DM. 401 
Interestingly, we show that esRAGE is preferentially lost with obesity. We found a 402 
significant group effect of obesity, whereby Overweight-Obese individuals possessed a 403 
higher cRAGE:esRAGE ratio compared to Lean individuals suggesting a preferential 404 
loss of esRAGE. Although we did not see any difference in cRAGE:esRAGE when 405 
stratifying by obesity status alone, esRAGE was 35% lower in Obese compared to Lean 406 
individuals whereas cRAGE was 24% lower in obese compared to Lean individuals. In 407 
addition, the Overweight-Obese, IGT-T2DM group resulted in the lowest concentration 408 
of esRAGE (Figure 2). Both BMI and body fat percentage displayed stronger 409 
correlations with esRAGE compared to cRAGE (Table 4).  410 
Production of esRAGE is regulated by the activity of two antagonistic splicing 411 
factors, heterogeneous nuclear ribonuclear protein A1 (hnRNPA1) and transformer-2 412 
beta (TRA2) (29). TRA2 promotes esRAGE production whereas hnRNPA1 413 
suppresses this activity.  Both TRA2 and hnRNPA1 are regulated by MAPK activity (1, 414 
6, 51) which is well known to be activated by RAGE signaling and exacerbated in 415 
obesity and insulin resistance (24). In addition, RAGE expression plays a critical role in 416 
adipose differentiation, hypertrophy, and inflammation (15, 33, 44). Therefore, adipose 417 
expansion and subsequent adipokine mediated inflammation may be suppressing the 418 
splicing mechanisms that regulate esRAGE. 419 
In support of this notion, TRA2 is reduced in the liver and skeletal muscle of 420 
obese, IGT-T2DM individuals (29, 35). In the current study, we found lower 421 
concentrations of esRAGE in obese individuals compared to lean. Additionally, esRAGE 422 
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was correlated to GDR (r=0.594, p<0.001), and body fat percentage (r=-0.311, 423 
p<0.001). These data suggest that both adipose, and skeletal muscle may be involved 424 
in RAGE splicing, and that the mechanisms involved become dysfunctional with obesity 425 
and insulin resistance. However, future studies are needed to identify the tissue- or, 426 
cell-specific sources of sRAGE isoform production, and what mechanisms are 427 
responsible for promoting and attenuating their release into the circulation.   428 
These findings demonstrate that the study of sRAGE isoforms remains an 429 
important area of research given both old and new data (30) reporting the potential role 430 
of sRAGE to impart physiological benefit and protection from cardiovascular and 431 
metabolic disease. It is evident that the mechanisms of sRAGE production are tightly 432 
regulated and that relatively small changes in circulating concentrations are linked to the 433 
natural history of T2DM. Herein, we are the first to characterize the circulating 434 
concentrations of the two most prominent sRAGE isoforms across the glucose tolerance 435 
continuum and demonstrate that total sRAGE, cRAGE, and cRAGE:esRAGE were 436 
associated with the proportional odds for progression across the glucose tolerance 437 
continuum using ordinal logistic regression. Our data are admittedly, limited by not 438 
being age-matched across all groups, as others have demonstrated that chronological 439 
age plays a significant role in sRAGE concentrations (36). However, juxtaposition of the 440 
T2DM phenotype against a young, lean healthy phenotype, demonstrates the degree by 441 
which circulating sRAGE isoforms, in obesity, states of impaired glucose tolerance, and 442 
advanced age deviate from optimum health. To tease the effect of age away from these 443 
other factors, we compared circulating sRAGE isoform concentrations across GTS while 444 
covarying for age. This analysis revealed that sRAGE remained significantly reduced in 445 
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T2DM despite the age difference between the T2DM and LHC groups. However, 446 
covarying for age did eliminate differences in total sRAGE and cRAGE between NGT 447 
and IGT, as well as eliminate all differences previously observed for esRAGE and 448 
cRAGE:esRAGE. This in addition to the inverse correlations between sRAGE measures 449 
and age, implicate age to effect circulating sRAGE. However, given that differences 450 
were still realized between T2DM and LHC individuals indicates that the T2DM 451 
phenotype, regardless of age, is characterized in part by reduced total sRAGE and 452 
cRAGE.  453 
We also acknowledge that the limitations of stratifying our data by BMI are such 454 
that BMI is less sensitive in detecting obesity than body fat percentage (38). However, 455 
when we stratified by body fat percentage cutoffs as previously reported by Romero-456 
Corral et al, the findings were consistent with the data that is currently reported using 457 
BMI (38).  458 
We were also unable to genotype our participants due to limited sample. This 459 
would have been an interesting addition to our data since multiple single nucleotide 460 
polymorphisms have been identified for RAGE and have been implicated in the 461 
development of obesity, and inflammation(23, 26). The SNP that involves glycine-serine 462 
switch at codon 82 (G82S) occurs in the ligand binding domain of RAGE and enhances 463 
its ability to promote RAGE activation (20). Koy et al demonstrated that lean and obese 464 
individuals with the S/S genotype possessed lower sRAGE compared to those with the 465 
G/S and G/G genotypes (26). Obese individuals in this cohort with the S/S genotype 466 
also possessed higher BMI and greater circulating CRP compared to those with the G/S 467 
and G/G genotypes (26). Our data demonstrate lower sRAGE isoform concentrations in 468 
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obese and T2DM individuals compared to lean healthy individuals. Unfortunately, we do 469 
not know if the G82S SNP is partly responsible for these differences in our sample on 470 
sRAGE. However, the frequency of glycine and serine alleles has not been previously 471 
shown to be different in T2DM compared to healthy individuals (23). Nevertheless, 472 
future studies should examine the effect of RAGE SNPs on the risk of obesity and 473 
diabetes development, and if this risk is related to sRAGE concentrations. The 474 
mechanism of how sRAGE concentrations are altered by SNPs in RAGE is also unclear 475 
and warrant future study. In addition, Kim OY et al only examined the relationship 476 
between the G82S SNP and total sRAGE concentrations and did not discriminate 477 
between the esRAGE and cRAGE isoforms (26). We have demonstrated here that 478 
dysregulation of these isoforms are associated with different phenotypes and therefore 479 
are likely under parallel regulation.  480 
In conclusion, the disproportionate reductions of cRAGE and esRAGE in T2DM 481 
and obesity, respectively, require further mechanistic study as our data implicate 482 
adiposity and insulin sensitivity, or both, to play a role in sRAGE biology. These finding 483 
suggest the presence of a failure in the sRAGE producing mechanisms with the onset of 484 
T2DM and obesity and requires further study. sRAGE was also strongly associated with 485 
the proportional odds ratio for progression through the glucose tolerance continuum, 486 
asserting sRAGE as a potential biomarker for T2DM. The long-term benefits for 487 
reporting these data are: 1) to help direct research efforts toward elucidating failed 488 
mechanisms underpinning the discrepancy in sRAGE isoform expression in T2DM and 489 
obesity and 2) to determine the efficacy of targeting these mechanisms for treatment of 490 
T2DM and obesity.  491 
 21 
 492 
 493 
 494 
 495 
 496 
 497 
Acknowledgements  498 
The authors would like to thank Karia Coleman, Victoria Meyers, Alec Chaves, Giamila 499 
Fantuzzi and Kelly Fuller of the University of Illinois at Chicago, for expert technical 500 
assistance. 501 
Funding  502 
This work was supported by the American Diabetes Association-Junior Faculty Award, 503 
1-14-JF-32 (JMH), CTSA grants UL1RR024989 and UL1RR029879, the Central Society 504 
for Clinical and Translational Research, the University of Chicago Diabetes Research 505 
Training Center (P30DK020595) and NIH grants R01AG12834 (JPK) R01NR007760 506 
(LQ), and R01DK109948 (JMH). Additional funding from EFSD / Amylin (TPJS) 507 
contributed to this work. 508 
Duality of Interests. The author reports no potential conflicts of interest relevant to 509 
this work. 510 
Author Contributions  511 
 ERM conceived of and designed the study, acquired and analyzed data, and drafted 512 
and reviewed the manuscript. VSS, JTM, BKB, SF, KK, CEF acquired and analyzed 513 
data and reviewed the manuscript. EW conceived of and designed the study, analyzed 514 
 22 
data, and reviewed the manuscript. SRK acquired and analyzed data, reviewed the 515 
manuscript, obtained funding and supervised the study. JPK, LQ, and TPJS acquired 516 
and analyzed data, drafted and reviewed the manuscript, obtained funding and 517 
supervised the study. JMH conceived of and designed the study, acquired and analyzed 518 
data, drafted and reviewed the manuscript, obtained funding and supervised the study. 519 
JMH is the guarantor of this work and, as such, had full access to all the data in the 520 
study and takes responsibility for the integrity of the data and the accuracy of the data 521 
analysis. 522 
 523 
 524 
 525 
 526 
 527 
 528 
 529 
 530 
 531 
 532 
 533 
 534 
 535 
 536 
 537 
 23 
 538 
 539 
 540 
 541 
 542 
 543 
References 544 
 545 
1. Akaike Y, Masuda K, Kuwano Y, Nishida K, Kajita K, Kurokawa K, Satake Y, 546 
Shoda K, Imoto I, and Rokutan K. HuR regulates alternative splicing of the TRA2beta 547 
gene in human colon cancer cells under oxidative stress. Mol Cell Biol 34: 2857-2873, 548 
2014. 549 
2. American Diabetes A. 2. Classification and Diagnosis of Diabetes. Diabetes 550 
Care 39 Suppl 1: S13-22, 2016. 551 
3. Basta G, Sironi AM, Lazzerini G, Del Turco S, Buzzigoli E, Casolaro A, 552 
Natali A, Ferrannini E, and Gastaldelli A. Circulating soluble receptor for advanced 553 
glycation end products is inversely associated with glycemic control and S100A12 554 
protein. J Clin Endocrinol Metab 91: 4628-4634, 2006. 555 
4. Biswas SK, Mohtarin S, Mudi SR, Anwar T, Banu LA, Alam SM, Fariduddin 556 
M, and Arslan MI. Relationship of Soluble RAGE with Insulin Resistance and Beta Cell 557 
Function during Development of Type 2 Diabetes Mellitus. Journal of diabetes research 558 
2015: 150325, 2015. 559 
5. Brix JM, Hollerl F, Kopp HP, Schernthaner GH, and Schernthaner G. The 560 
soluble form of the receptor of advanced glycation endproducts increases after bariatric 561 
surgery in morbid obesity. Int J Obes (Lond) 36: 1412-1417, 2012. 562 
6. Buxade M, Parra JL, Rousseau S, Shpiro N, Marquez R, Morrice N, Bain J, 563 
Espel E, and Proud CG. The Mnks are novel components in the control of TNF alpha 564 
biosynthesis and phosphorylate and regulate hnRNP A1. Immunity 23: 177-189, 2005. 565 
7. Cai W, Ramdas M, Zhu L, Chen X, Striker GE, and Vlassara H. Oral advanced 566 
glycation endproducts (AGEs) promote insulin resistance and diabetes by depleting the 567 
antioxidant defenses AGE receptor-1 and sirtuin 1. Proc Natl Acad Sci U S A 109: 568 
15888-15893, 2012. 569 
8. Cassese A, Esposito I, Fiory F, Barbagallo AP, Paturzo F, Mirra P, Ulianich 570 
L, Giacco F, Iadicicco C, Lombardi A, Oriente F, Van Obberghen E, Beguinot F, 571 
 24 
Formisano P, and Miele C. In skeletal muscle advanced glycation end products 572 
(AGEs) inhibit insulin action and induce the formation of multimolecular complexes 573 
including the receptor for AGEs. J Biol Chem 283: 36088-36099, 2008. 574 
9. Choi KM, Han KA, Ahn HJ, Hwang SY, Hong HC, Choi HY, Yang SJ, Yoo HJ, 575 
Baik SH, Choi DS, and Min KW. Effects of exercise on sRAGE levels and 576 
cardiometabolic risk factors in patients with type 2 diabetes: a randomized controlled 577 
trial. J Clin Endocrinol Metab 97: 3751-3758, 2012. 578 
10. Corbett GT, Gonzalez FJ, and Pahan K. Activation of peroxisome proliferator-579 
activated receptor alpha stimulates ADAM10-mediated proteolysis of APP. Proc Natl 580 
Acad Sci U S A 112: 8445-8450, 2015. 581 
11. Deane RJ. Is RAGE still a therapeutic target for Alzheimer's disease? Future 582 
Med Chem 4: 915-925, 2012. 583 
12. Di Pino A, Urbano F, Zagami RM, Filippello A, Di Mauro S, Piro S, Purrello F, 584 
and Rabuazzo AM. Low Endogenous Secretory Receptor for Advanced Glycation End-585 
Products Levels Are Associated With Inflammation and Carotid Atherosclerosis in 586 
Prediabetes. J Clin Endocrinol Metab 101: 1701-1709, 2016. 587 
13. Dozio E, Briganti S, Delnevo A, Vianello E, Ermetici F, Secchi F, Sardanelli 588 
F, Morricone L, Malavazos AE, and Corsi Romanelli MM. Relationship between 589 
soluble receptor for advanced glycation end products (sRAGE), body composition and 590 
fat distribution in healthy women. Eur J Nutr 2016. 591 
14. Falcone C, Emanuele E, D'Angelo A, Buzzi MP, Belvito C, Cuccia M, and 592 
Geroldi D. Plasma levels of soluble receptor for advanced glycation end products and 593 
coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 25: 1032-594 
1037, 2005. 595 
15. Gaens KH, Goossens GH, Niessen PM, van Greevenbroek MM, van der 596 
Kallen CJ, Niessen HW, Rensen SS, Buurman WA, Greve JW, Blaak EE, van 597 
Zandvoort MA, Bierhaus A, Stehouwer CD, and Schalkwijk CG. Nepsilon-598 
(carboxymethyl)lysine-receptor for advanced glycation end product axis is a key 599 
modulator of obesity-induced dysregulation of adipokine expression and insulin 600 
resistance. Arterioscler Thromb Vasc Biol 34: 1199-1208, 2014. 601 
16. Galichet A, Weibel M, and Heizmann CW. Calcium-regulated intramembrane 602 
proteolysis of the RAGE receptor. Biochem Biophys Res Commun 370: 1-5, 2008. 603 
17. Grossin N, Wautier MP, Meas T, Guillausseau PJ, Massin P, and Wautier JL. 604 
Severity of diabetic microvascular complications is associated with a low soluble RAGE 605 
level. Diabetes & metabolism 34: 392-395, 2008. 606 
18. Guclu M, Ali A, Eroglu DU, Buyukuysal SO, Cander S, and Ocak N. Serum 607 
Levels of sRAGE Are Associated with Body Measurements, but Not Glycemic 608 
Parameters in Patients with Prediabetes. Metab Syndr Relat Disord 14: 33-39, 2016. 609 
 25 
19. Haffner SM. Epidemiology of type 2 diabetes: risk factors. Diabetes Care 21 610 
Suppl 3: C3-6, 1998. 611 
20. Hofmann MA, Drury S, Hudson BI, Gleason MR, Qu W, Lu Y, Lalla E, Chitnis 612 
S, Monteiro J, Stickland MH, Bucciarelli LG, Moser B, Moxley G, Itescu S, Grant 613 
PJ, Gregersen PK, Stern DM, and Schmidt AM. RAGE and arthritis: the G82S 614 
polymorphism amplifies the inflammatory response. Genes Immun 3: 123-135, 2002. 615 
21. Huang KP, Chen C, Hao J, Huang JY, Liu PQ, and Huang HQ. AGEs-RAGE 616 
system down-regulates Sirt1 through the ubiquitin-proteasome pathway to promote FN 617 
and TGF-beta1 expression in male rat glomerular mesangial cells. Endocrinology 156: 618 
268-279, 2015. 619 
22. Huang M, Que Y, and Shen X. Correlation of the plasma levels of soluble RAGE 620 
and endogenous secretory RAGE with oxidative stress in pre-diabetic patients. J 621 
Diabetes Complications 29: 422-426, 2015. 622 
23. Hudson BI, Stickland MH, and Grant PJ. Identification of polymorphisms in the 623 
receptor for advanced glycation end products (RAGE) gene: prevalence in type 2 624 
diabetes and ethnic groups. Diabetes 47: 1155-1157, 1998. 625 
24. Jialal I, Adams-Huet B, and Pahwa R. Selective increase in monocyte p38 626 
mitogen-activated protein kinase activity in metabolic syndrome. Diab Vasc Dis Res 13: 627 
93-96, 2016. 628 
25. Karstoft K, Winding K, Knudsen SH, James NG, Scheel MM, Olesen J, Holst 629 
JJ, Pedersen BK, and Solomon TP. Mechanisms behind the superior effects of 630 
interval vs continuous training on glycaemic control in individuals with type 2 diabetes: a 631 
randomised controlled trial. Diabetologia 57: 2081-2093, 2014. 632 
26. Kim OY, Jo SH, Jang Y, Chae JS, Kim JY, Hyun YJ, and Lee JH. G allele at 633 
RAGE SNP82 is associated with proinflammatory markers in obese subjects. Nutr Res 634 
29: 106-113, 2009. 635 
27. Kitada M, and Koya D. SIRT1 in Type 2 Diabetes: Mechanisms and Therapeutic 636 
Potential. Diabetes Metab J 37: 315-325, 2013. 637 
28. Lee HR, Shin HK, Park SY, Kim HY, Lee WS, Rhim BY, Hong KW, and Kim 638 
CD. Cilostazol suppresses beta-amyloid production by activating a disintegrin and 639 
metalloproteinase 10 via the upregulation of SIRT1-coupled retinoic acid receptor-beta. 640 
J Neurosci Res 92: 1581-1590, 2014. 641 
29. Liu XY, Li HL, Su JB, Ding FH, Zhao JJ, Chai F, Li YX, Cui SC, Sun FY, Wu 642 
ZY, Xu P, and Chen XH. Regulation of RAGE splicing by hnRNP A1 and Tra2beta-1 643 
and its potential role in AD pathogenesis. J Neurochem 133: 187-198, 2015. 644 
 26 
30. Liu Y, Yu M, Zhang L, Cao Q, Song Y, Liu Y, and Gong J. Soluble receptor for 645 
advanced glycation end products mitigates vascular dysfunction in spontaneously 646 
hypertensive rats. Mol Cell Biochem 419: 165-176, 2016. 647 
31. Mahmoud AM, Szczurek MR, Blackburn BK, Mey JT, Chen Z, Robinson AT, 648 
Bian JT, Unterman TG, Minshall RD, Brown MD, Kirwan JP, Phillips SA, and Haus 649 
JM. Hyperinsulinemia augments endothelin-1 protein expression and impairs 650 
vasodilation of human skeletal muscle arterioles. Physiol Rep 4: 2016. 651 
32. Metz VV, Kojro E, Rat D, and Postina R. Induction of RAGE shedding by 652 
activation of G protein-coupled receptors. PLoS One 7: e41823, 2012. 653 
33. Monden M, Koyama H, Otsuka Y, Morioka T, Mori K, Shoji T, Mima Y, 654 
Motoyama K, Fukumoto S, Shioi A, Emoto M, Yamamoto Y, Yamamoto H, 655 
Nishizawa Y, Kurajoh M, Yamamoto T, and Inaba M. Receptor for advanced 656 
glycation end products regulates adipocyte hypertrophy and insulin sensitivity in mice: 657 
involvement of Toll-like receptor 2. Diabetes 62: 478-489, 2013. 658 
34. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ, Chow WS, Stern D, and 659 
Schmidt AM. Suppression of accelerated diabetic atherosclerosis by the soluble 660 
receptor for advanced glycation endproducts. Nat Med 4: 1025-1031, 1998. 661 
35. Pihlajamaki J, Lerin C, Itkonen P, Boes T, Floss T, Schroeder J, Dearie F, 662 
Crunkhorn S, Burak F, Jimenez-Chillaron JC, Kuulasmaa T, Miettinen P, Park PJ, 663 
Nasser I, Zhao Z, Zhang Z, Xu Y, Wurst W, Ren H, Morris AJ, Stamm S, Goldfine 664 
AB, Laakso M, and Patti ME. Expression of the splicing factor gene SFRS10 is 665 
reduced in human obesity and contributes to enhanced lipogenesis. Cell Metab 14: 208-666 
218, 2011. 667 
36. Prakash J, Pichchadze G, Trofimov S, and Livshits G. Age and genetic 668 
determinants of variation of circulating levels of the receptor for advanced glycation end 669 
products (RAGE) in the general human population. Mech Ageing Dev 145: 18-25, 2015. 670 
37. Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A, Reiss 671 
K, Saftig P, and Bianchi ME. A soluble form of the receptor for advanced glycation 672 
endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form 673 
by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 22: 3716-674 
3727, 2008. 675 
38. Romero-Corral A, Somers VK, Sierra-Johnson J, Thomas RJ, Collazo-676 
Clavell ML, Korinek J, Allison TG, Batsis JA, Sert-Kuniyoshi FH, and Lopez-677 
Jimenez F. Accuracy of body mass index in diagnosing obesity in the adult general 678 
population. Int J Obes (Lond) 32: 959-966, 2008. 679 
39. Schmidt AM, Yan SD, Yan SF, and Stern DM. The multiligand receptor RAGE 680 
as a progression factor amplifying immune and inflammatory responses. Journal of 681 
Clinical Investigation 108: 949-955, 2001. 682 
 27 
40. Selvin E, Halushka MK, Rawlings AM, Hoogeveen RC, Ballantyne CM, 683 
Coresh J, and Astor BC. sRAGE and risk of diabetes, cardiovascular disease, and 684 
death. Diabetes 62: 2116-2121, 2013. 685 
41. Solomon TP, Haus JM, Kelly KR, Cook MD, Filion J, Rocco M, Kashyap SR, 686 
Watanabe RM, Barkoukis H, and Kirwan JP. A low-glycemic index diet combined with 687 
exercise reduces insulin resistance, postprandial hyperinsulinemia, and glucose-688 
dependent insulinotropic polypeptide responses in obese, prediabetic humans. Am J 689 
Clin Nutr 92: 1359-1368, 2010. 690 
42. Solomon TP, Knudsen SH, Karstoft K, Winding K, Holst JJ, and Pedersen 691 
BK. Examining the effects of hyperglycemia on pancreatic endocrine function in 692 
humans: evidence for in vivo glucotoxicity. J Clin Endocrinol Metab 97: 4682-4691, 693 
2012. 694 
43. Solomon TP, Malin SK, Karstoft K, Knudsen SH, Haus JM, Laye MJ, and 695 
Kirwan JP. Association between cardiorespiratory fitness and the determinants of 696 
glycemic control across the entire glucose tolerance continuum. Diabetes Care 38: 921-697 
929, 2015. 698 
44. Song F, Hurtado del Pozo C, Rosario R, Zou YS, Ananthakrishnan R, Xu X, 699 
Patel PR, Benoit VM, Yan SF, Li H, Friedman RA, Kim JK, Ramasamy R, Ferrante 700 
AW, Jr., and Schmidt AM. RAGE regulates the metabolic and inflammatory response 701 
to high-fat feeding in mice. Diabetes 63: 1948-1965, 2014. 702 
45. Su XD, Li SS, Tian YQ, Zhang ZY, Zhang GZ, and Wang LX. Elevated serum 703 
levels of advanced glycation end products and their monocyte receptors in patients with 704 
type 2 diabetes. Arch Med Res 42: 596-601, 2011. 705 
46. Tam XH, Shiu SW, Leng L, Bucala R, Betteridge DJ, and Tan KC. Enhanced 706 
expression of receptor for advanced glycation end-products is associated with low 707 
circulating soluble isoforms of the receptor in Type 2 diabetes. Clin Sci (Lond) 120: 81-708 
89, 2011. 709 
47. Tang SC, Yeh SJ, Tsai LK, Hu CJ, Lien LM, Peng GS, Yang WS, Chiou HY, 710 
and Jeng JS. Cleaved but not endogenous secretory RAGE is associated with outcome 711 
in acute ischemic stroke. Neurology 86: 270-276, 2016. 712 
48. Thomas MC, Woodward M, Neal B, Li Q, Pickering R, Marre M, Williams B, 713 
Perkovic V, Cooper ME, Zoungas S, Chalmers J, and Hillis GS. Relationship 714 
between levels of advanced glycation end products and their soluble receptor and 715 
adverse outcomes in adults with type 2 diabetes. Diabetes Care 38: 1891-1897, 2015. 716 
49. Tippmann F, Hundt J, Schneider A, Endres K, and Fahrenholz F. Up-717 
regulation of the alpha-secretase ADAM10 by retinoic acid receptors and acitretin. 718 
FASEB J 23: 1643-1654, 2009. 719 
 28 
50. Uribarri J, Cai W, Ramdas M, Goodman S, Pyzik R, Chen X, Zhu L, Striker 720 
GE, and Vlassara H. Restriction of advanced glycation end products improves insulin 721 
resistance in human type 2 diabetes: potential role of AGER1 and SIRT1. Diabetes 722 
Care 34: 1610-1616, 2011. 723 
51. van der Houven van Oordt W, Diaz-Meco MT, Lozano J, Krainer AR, Moscat 724 
J, and Caceres JF. The MKK(3/6)-p38-signaling cascade alters the subcellular 725 
distribution of hnRNP A1 and modulates alternative splicing regulation. J Cell Biol 149: 726 
307-316, 2000. 727 
52. Warner P. Ordinal logistic regression. J Fam Plann Reprod Health Care 34: 169-728 
170, 2008. 729 
53. Williamson DL, Dungan CM, Mahmoud AM, Mey JT, Blackburn BK, and 730 
Haus JM. Aberrant REDD1-mTORC1 responses to insulin in skeletal muscle from Type 731 
2 diabetics. Am J Physiol Regul Integr Comp Physiol 309: R855-863, 2015. 732 
54. Xu XY, Deng CQ, Wang J, Deng XJ, Xiao Q, Li Y, He Q, Fan WH, Quan FY, 733 
Zhu YP, Cheng P, and Chen GJ. Plasma Levels of Soluble Receptor for Advanced 734 
Glycation End Products in Alzheimer Disease. Int J Neurosci 1-18, 2016. 735 
55. Yamamoto Y, Miura J, Sakurai S, Watanabe T, Yonekura H, Tamei H, 736 
Matsuki H, Obata Ki, Uchigata Y, Iwamoto Y, Koyama H, and Yamamoto H. 737 
Assaying Soluble Forms of Receptor for Advanced Glycation End Products. 738 
Arteriosclerosis, Thrombosis, and Vascular Biology 27: e33-e34, 2007. 739 
56. Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, Yasui K, 740 
Takeuchi M, Makita Z, Takasawa S, Okamoto H, Watanabe T, and Yamamoto H. 741 
Novel splice variants of the receptor for advanced glycation end-products expressed in 742 
human vascular endothelial cells and pericytes, and their putative roles in diabetes-743 
induced vascular injury. Biochem J 370: 1097-1109, 2003. 744 
 745 
 746 
 747 
 748 
 749 
 750 
 751 
 752 
 753 
 754 
 755 
 756 
 757 
 758 
 759 
 760 
 29 
 761 
 762 
 763 
 764 
 765 
 766 
 767 
 768 
 769 
 770 
 771 
 772 
 773 
 774 
 775 
 776 
 777 
Figure and Table Legends 778 
 779 
Figure 1 Soluble RAGE Isoforms According to Glucose Tolerance Status.  780 
Subjects were stratified by glucose tolerance status NGT (n = 150): Normal Glucose 781 
Tolerance, IGT (n = 30): Impaired Glucose Tolerance, T2DM (n = 94): Type Two 782 
Diabetes Mellitus. Comparisons between groups were made for total sRAGE (A), 783 
cRAGE (B), esRAGE (C) and cRAGE: esRAGE ratio (D). Differences between groups 784 
were analyzed by one-way ANOVA and Bonferroni post hoc tests as necessary. Bars 785 
represent MEAN (SD). *p < 0.05, **p < 0.01, and ***p < 0.0001 vs. NGT. 786 
 787 
Figure 2 Effects of Glucose Tolerance and BMI on sRAGE isoforms. 788 
Subject groups were collapsed into NGT vs. IGT-T2DM designations and further 789 
stratified by BMI (Lean vs. Overweight-Obese). Lean, NGT n = 74; Overweight-Obese, 790 
NGT n = 76; Lean, IGT-T2DM n = 16; Overweight-Obese, IGT-T2DM n = 105. Group 791 
comparisons were made for total sRAGE (A), cRAGE (B), esRAGE (C), and cRAGE: 792 
esRAGE ratio (D) using two-way ANOVA and Bonferroni post hoc tests as necessary. 793 
Bars represent MEAN (SD). *p < 0.05, **p < 0.01, and ***p < 0.0001 vs. NGT; #p < 794 
0.05, ##p < 0.01, and ###p < 0.0001 vs. Lean. 795 
 796 
Table 1 Metabolic characteristics. 797 
Data are presented as MEAN (SD). Normally distributed data were analyzed by one-798 
way ANOVA and Bonferroni adjustments for multiple comparisons. Non-normally 799 
distributed variables (as indicated by ^) were analyzed using Kruskal-Wallis test and 800 
Bonferroni adjustments for multiple comparisons. NGT (n = 150): Normal Glucose 801 
Tolerance, IGT (n = 30): Impaired Glucose Tolerance, T2DM (n = 94): Type Two 802 
Diabetes Mellitus. BMI: body mass index; VO2Max: Maximal Aerobic Fitness; BF%: Body 803 
Fat Percentage; Fat mass; 2-h OGTT Glucose iAUC: 2 Hour Oral Glucose Tolerance 804 
Test Glucose Incremental Area Under the Curve; 2-h OGTT Glucose: Blood glucose at 805 
2-h time point of OGTT; HbA1c : Glycated Hemoglobin; HOMA-IR: Homeostatic Model 806 
 30 
Assessment of Insulin Resistance; GDR: Hyperinsulinemic-Euglycemic Clamp Derived 807 
Glucose Disposal Rate; hs-CRP: High Sensitivity C-Reactive Protein. **p < 0.01, and 808 
***p < 0.0001 vs. NGT; #p < 0.05, ##p < 0.01, and ###p < 0.0001 vs. IGT. 809 
 810 
Table 2 Descriptive Demographics. 811 
Frequencies of demographic descriptors of individuals grouped by glucose tolerance 812 
status. ***p <0.0001 vs NGT. 813 
 814 
Table 3 Soluble RAGE isoforms and proportional odds for developing T2DM. 815 
Total sRAGE, cRAGE, esRAGE and sRAGE Ratio (cRAGE: esRAGE) were used to 816 
construct models 1, 2, 3 and 4 respectively. The values for total sRAGE, cRAGE and 817 
esRAGE were multiplied by 100 before entering them into the models. Models were 818 
corrected for age and race where Caucasian and lean were used as reference, 819 
respectively. OR: Odds Ratio, CI: confidence interval, Other: Hispanic/Asian 820 
 821 
Table 4 Correlations Between sRAGE Isoforms and Metabolic Characteristics. 822 
Bivariate correlation analyses were used to examine relationships between sRAGE 823 
isoforms and metabolic parameters. Pearson correlation coefficients were performed 824 
unless denoted (^) which were analyzed by Spearman’s Rho.825 
 31 
Table 1 Metabolic characteristics. 826 
   Variable, units NGT IGT T2DM 
Sex, M/F  79/71 10/20 47/47 
Age, y  39 (SD 17) 61 ± (SD 10)*** 57 ± (SD 9)*** 
BMI, kg/m2  27.0 (SD 6.2) 34.8 (SD 4.8)*** 32.6 ± (SD 7.3)*** 
VO2Max, mL/kg/min  32.6 (SD 10.4) 23.3 (SD 6.4)*** 26.3 (SD 6.6)*** 
BF, %  33.0 (SD 9.4) 43.2 ± (SD 8.1)*** 36.0 (SD 9.5)## 
Fat Mass, kg 29.0 (SD 12.9) 40.7 (SD 8.5)*** 31.7 (SD 12.4)## 
Lean Body Mass, kg  55.3 (SD 12.1) 54.2 (SD 12.0) 57.9 (SD 11.5) 
2-h OGTT Glucose, mg/dL  114 (SD 22.5) 162 (SD 16.9)*** 281 (SD 67.4)***### 
2-h OGTT Glucose iAUC, AU  4201 (SD 2083) 7322 (SD 2639)** 5133 (SD 5567)# 
HbA1C, %  5.4 (SD 0.46) 5.7 (SD 0.52) 7.1 (SD 1.6)***### 
HbA1C, mmol/mol  35.7 (SD 4.98) 38.5 (SD 5.71) 54.5 (SD 17.7)***### 
Fasting Glucose, mg/dL^ 93 (SD 10.9) 97 (SD 11.7) 151 (SD 61.4)***### 
Fasting Insulin, mU/L^ 9.5 (SD 6.3) 15.9 (SD 11.6)** 13.5 (SD 6.6)*** 
HOMA-IR, AU^ 2.2 (SD 1.6) 4.7 (SD 5.0)*** 5.0 (SD 3.2)*** 
Matsuda Index, AU^ 4.7 (SD 3.1) 2.5 (SD 1.5)*** 3.1 (SD 1.9)*** 
GDR, mg/kg/min^ 4.9 (SD 2.3) 2.9 (SD 1.2)** 2.6 (SD 0.96)** 
hs-CRP, mg/L  2.2 (SD 1.9) 2.8 (SD 1.6) 2.6 (SD 2.6) 
 827 
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Table 2 Descriptive Demographics. 828 
 829 
  NGT (n=150) IGT (n=30) T2DM (n=94) 
Variable n % n % n % 
Age (y) 39 (SD 17) 61 (SD 10)*** 57 (SD 9)*** 
  Young (18-35 y) 88 59 1 3 1 1 
  Middle age (36-64 y) 44 29 19 63 68 72 
  Old (≥ 65 y) 18 12 10 33 25 27 
Gender 
        Male 79 53 10 35 47 50 
  Female 71 47 20 67 47 50 
Race 
        White 107 71 21 70 63 67 
  Black 17 11 7 23 31 33 
  Hispanic 10 7 2 7 0 0 
  Asian 16 11 0 0 0 0 
Obesity (kg/m2) 27.0 (SD 6.2) 34.8 (SD 4.8)* 32.6 (SD 7.3)* 
  Lean (18-24) 74 49 1 3 15 16 
  Overweight (25-29) 27 18 2 7 24 26 
  Obese (≥ 30) 49 33 27 90 55 59 
  830 
 831 
 832 
 833 
 834 
 835 
 836 
 837 
 838 
 839 
 840 
 841 
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Table 3 Soluble RAGE isoforms and proportional odds for developing T2DM. 842 
 843 
 
Model 1 Model 2 Model 3 Model 4 
Variable OR 95% CI P OR 95% CI P OR 95% CI P OR 95% CI P 
Age 1.06 1.03-1.08 <.001 1.06 1.03-1.08 <.001 1.07 1.05-1.10 <.001 1.06 1.04-1.09 <.001 
Race  
              Black 3.43 1.69-6.96 <.001 4.11 1.93-8.75 <.001 3.57 1.74-7.31 <.001 4.04 1.91-8.53 <.001 
  Other (Hispanic/Asian) 0.30 0.06-6.96 0.139 0.31 0.06-1.55 0.155 0.36 0.07-1.72 0.199 0.40 0.08-1.93 0.255 
Obesity 
              Overweight 1.39 0.58-3.35 0.459 1.58 0.64-3.87 0.322 1.29 0.53-3.16 0.576 1.79 0.72-4.45 0.208 
  Obese 1.08 0.46-2.50 0.864 1.34 0.57-3.15 0.505 1.06 0.45-2.53 0.890 1.68 0.69-4.07 0.253 
Total sRAGE 0.91 0.85-0.97 0.003 - - - - - - - - - 
cRAGE - - - 0.84 0.77-0.92 <.001 
    
- - - 
esRAGE - - - 
    
0.93 0.78-1.10 0.374 - - - 
cRAGE/esRAGE - - - - - - - - - 0.74 0.58-0.96 0.022 
C-statistics 0.782 0.805 0.773 0.784 
 844 
 845 
 846 
 847 
 848 
 849 
 850 
 851 
 852 
 853 
 854 
 855 
 856 
 857 
 858 
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Table 4 Correlations Between sRAGE Isoforms and Metabolic Characteristics. 859 
 860 
 
Total sRAGE (pg/ml) 
 
 cRAGE (pg/mL) 
 
esRAGE (pg/mL) 
 
cRAGE:esRAGE 
  r p 
 
r p 
 
r p 
 
r p 
Age (y) -0.368 < 0.001   -0.387 < 0.001   -0.206 0.001   -0.254 <0.0001 
VO2Max (mL/kg/min)  0.231 0.002 
 
0.291 < 0.001 
 
0.156 0.039 
 
0.202 0.007 
BMI (kg/m2) -0.225 < 0.001 
 
-0.158 0.010 
 
-0.288 < 0.001 
 
0.140 0.023 
BF (%) -0.288 < 0.001 
 
-0.227 0.001 
 
-0.311 < 0.001 
 
-0.004 0.953 
LBM (kg) 0.066 0.351 
 
0.075 0.297 
 
-0.058 0.414 
 
0.136 0.058 
Fat Mass (kg) -0.211 0.003 
 
-0.130 0.071 
 
-0.312 < 0.001 
 
0.101 0.158 
2-h OGTT (mg/dL) -0.233 0.002 
 
-0.292 < 0.001 
 
-0.075 0.332 
 
-0.253 0.001 
2-h OGTT iAUC (AU) -0.068 0.185 
 
0.078 0.300 
 
-0.279 < 0.001 
 
0.424 < 0.001 
HbA1C (%) -0.200 0.006 
 
-0.183 0.013 
 
-0.153 0.036 
 
-0.001 0.989 
FPG (mg/dL) -0.292 < 0.001 
 
-0.337 < 0.001 
 
-0.134 0.046 
 
-0.233 < 0.001 
FPI (mU/L) -0.184 0.006 
 
-0.200 0.003 
 
-0.107 0.116 
 
-0.068 0.322 
HOMA-IR (AU) -0.255 < 0.001 
 
-0.291 < 0.001 
 
-0.121 0.075 
 
-0.154 0.024 
Matsuda Index (AU) 0.214 0.005 
 
0.183 0.018 
 
0.187 0.015 
 
-0.007 0.928 
GDR (mg/kg/min) 0.472 < 0.001 
 
0.343 0.003 
 
0.594 < 0.001 
 
-0.276 0.018 
CRP (mg/L) -0.220 0.012   -0.138 0.119   -0.274 0.002   0.140 0.113 
 861 
 862 
 863 
 864 
Figure 1 Soluble RAGE Isoforms According to Glucose Tolerance Status. 
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Figure 2 Effects of Glucose Tolerance and BMI on sRAGE isoforms. 
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